Results 111 to 120 of about 11,787 (237)

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Evaluation of Luteolin Nanosuspensions on Pharmacokinetics of Atorvastatin: Drug-Drug Interactions Using Rat Models

International Journal of Nanomedicine
You Liang,* Bo Sun,* Min Yang, Xiaona Meng, Meng Wang, Lijuan Yang, Bandar AI-Hamyari, Yuqian Zhang, Yutong Shen, Shengnan Meng Department of Pharmaceutics, School of Pharmacy, China Medical University, Shenyang, 110122, People’s Republic of ...
Liang Y, Sun B, Yang M, Meng X, Wang M, Yang L, AI-Hamyari B, Zhang Y, Shen Y, Meng S   +9 more
doaj  

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Structure of pregnancy physiologically based pharmacokinetic (p-PBPK) model.

, 2015
Structure of pregnancy physiologically based pharmacokinetic (p-PBPK) model.
Saeed Alqahtani (802779), Amal Kaddoumi (802780)   +1 more
core   +1 more source

Evaluating Thiram‐Induced Embryotoxicity Using Integrated In Silico, In Vitro, and Transcriptomic Approaches

Environmental Toxicology, EarlyView.
ABSTRACT Long‐term exposure to low‐dose food contact materials (FCMs) has raised concerns regarding developmental toxicity. In the present study, we prioritized FCMs with potential developmental toxicity using a weight‐of‐evidence computational model, which predicted 127 chemicals to be of high concern.
Chia‐Chi Ho, Chun‐Wei Tung, B. Linju Yen, Chen‐Yi Weng, Ju‐Hsin Hsu, Ming‐Hsien Tsai, Salim Arrokhman, Pinpin Lin   +7 more
wiley   +1 more source

Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases

Scientific Reports
The purpose of this study was to develop and validate a physiologically based pharmacokinetic (PBPK) model combined with an EGFR occupancy (EO) model for osimertinib (OSI) to predict plasma trough concentration (Ctrough) and the intracranial time-course ...
Feng Liang, Yimei Zhang, Qian Xue, Xiaoling Zhang   +3 more
doaj   +1 more source

Microplastics and the Endocrine–Metabolic Interface: Novel Diagnostic Tools Targeting Thyroid–Adipose Axis

Environmental Toxicology, EarlyView.
ABSTRACT Microplastics (MPs) have been identified as major environmental contaminants that can affect organisms directly and act as carriers of particles and chemical additives, thereby aggravating endocrine networks that coordinate metabolic homeostasis.
Sunday Amos Onikanni, Babasola Aiyeku, Marjorie Dardis Murucci, Temitope Aribigbola, Kenia Bispo, Oluwatosin Stella Olayinka, Rômulo Sperduto Dezonne, Sara Gemini Piperni, Paula Soares, Denise Pires de Carvalho, Leandro Miranda‐Alves   +10 more
wiley   +1 more source

EuroMix PBPK model for combined exposures

, 2019
In this paper documents the structure and default parameter values of the EuroMix PBPK model implemented in the MCRA platform for rats and humans. A version allowing apportionment of results by exposure routes is also described. Finally, the extensions needed to describe pharmacokinetic interactions between pairs or triplets of substance are discussed.
Bois, F.Y., Tebby, C., Brochot, C.
openaire   +2 more sources

Integration of Machine Learning With PBPK and QSAR Modeling Approaches to Facilitate Drug Discovery and Development

CPT: Pharmacometrics & Systems Pharmacology
This review examines the application of machine learning (ML) in physiologically based pharmacokinetic (PBPK) modeling through improved prediction of input parameters, particularly via quantitative structure–activity relationship (QSAR) models, for ...
Xinyue Chen, Zhoumeng Lin
doaj   +1 more source

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

British Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux, Solenn Gousset, Beltrán Alvarez, Monica Baiula, Wouter Bakker, Andrea Bedini, Monir Bertayli, Divakar Budda, Robert Carr, Elisabetta Cuna, Óscar Díaz, Nina Donner, Jesús Giraldo, Geert‐Jan Groeneveld, Berfin Gülave, David Guydan, Hemme Hijma, Rafael Maldonado, Pedro Renault, Carlos Rinaudo, Jeroen Elaissaiss‐Schaap, Athan Spiros, Sara Stoeber, Petri Takkala, Daan van Valkengoed, Coen van Hasselt, Elizabeth (Liesbeth) C.M. de Lange   +26 more
wiley   +1 more source